- Home
- TOP vs XLO Comparison
TOP vs XLO Comparison
Compare TOP & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TOP | XLO |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.0M | 41.8M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TOP | XLO |
|---|---|---|
| Price | $1.15 | $0.67 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 46.8K | ★ 528.0K |
| Earning Date | 01-26-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $3,329,256.00 | ★ $31,804,000.00 |
| Revenue This Year | N/A | $589.60 |
| Revenue Next Year | N/A | $38.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 588.40 |
| 52 Week Low | $1.00 | $0.62 |
| 52 Week High | $3.33 | $1.70 |
Technical Indicators
Market Signals| Indicator | TOP | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 54.02 | 35.82 |
| Support Level | $1.10 | $0.68 |
| Resistance Level | $1.24 | $0.73 |
| Average True Range (ATR) | 0.05 | 0.03 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 59.09 | 2.13 |
Price Performance
Historical ComparisonAbout TOP TOP Financial Group Limited
TOP Financial Group Ltd is an online brokerage firm in Hong Kong specializing in trading local and overseas equities, futures, and options products. The Company generates brokerage commission income by enabling its customers to trade on multiple exchanges present globally. The company operates in only one segment which is the futures brokerage service.
About XLO Xilio Therapeutics Inc.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.